ライフサイエンスコーパス: mammoplasty

1 ity of normal tissue obtained from reduction mammoplasty.

2 east epithelial cells (HBECs) from reduction mammoplasty.

3 normal (nonlactating) samples from reductive mammoplasties.

4 n-genitoplasty titles, 35 were mastectomy, 6 mammoplasty, 21 facial feminization, and 31 voice/cartil

5 sion in a series of specimens from reduction mammoplasty, adenosis, ductal carcinoma in situ, and inf

6 normal breast tissue samples from reduction mammoplasties and in two independent tissue microarrays

7 Human skin was obtained from reduction mammoplasties and prepared for culture.

8 d GnRH analogs and surgical therapy includes mammoplasty and phalloplasty.

9 significant association between augmentation mammoplasty and SSc, and are consistent with those repor

10 ng breast fibroblasts derived from reduction mammoplasty and tumor tissues, and human umbilical endot

11 s within tumors and in tissue from reduction mammoplasties, and by epithelial-derived tumor cells.

12 parately purified from a set of 10 reduction mammoplasties by using a double antibody magnetic affini

13 combining partial mastectomy with reduction mammoplasty could provide a safe oncologic procedure wit

14 Whereas inclusion of normal reduction mammoplasty fibroblasts inhibit or retard morphological

15 Samples from bilateral reduction mammoplasty from 10 women without any clinical, radiolog

16 , established from tissue taken at reduction mammoplasty from three individuals.

17 s were also selected as a control (reduction mammoplasty group).

18 She underwent bilateral reduction mammoplasty in June 1995 to treat progressive breast enl

19 re providing data on history of augmentation mammoplasty, including possible complications of the pro

20 ary epithelial cells enriched from reduction mammoplasties (n = 9).

21 ed by benign tissue, and finally followed by mammoplasty negative control samples.

22 diseased tissue (e.g. MCF10A) and reduction mammoplasty of normal breast tissue (e.g. 184A1) to furt

23 rom breast cancer patients or from reduction mammoplasty operations expressed comparable estradiol 2-

24 from 55 donors that had undergone reduction mammoplasties or risk reduction mastectomies.

25 collected from women who underwent reduction mammoplasty or breast cancer surgery.

26 reast epithelial cells from either reduction mammoplasty or nonmalignant breast cell lines, we observ

27 partial mastectomy and concurrent reduction mammoplasty performed at our institution from 2000 to 20

28 837 cases reported a history of augmentation mammoplasty prior to diagnosis of SSc, compared with 31

29 ve simultaneous partial mastectomy/reduction mammoplasty procedures were performed in 79 patients.

30 r who have previously undergone augmentation mammoplasty result in a high prevalence of capsular cont

31 m 29 noncancer patients undergoing reduction mammoplasty served as controls.

32 sues and from epithelial cells purified from mammoplasty specimens.

33 and evaluation of the skin during reduction mammoplasty surgery in two patients.

34 partial mastectomy with concurrent reduction mammoplasty technique is a viable option for breast cons

35 degrees of risk (those undergoing reduction mammoplasties, those with atypical hyperplastic prolifer

36 thelial cells (HMEC) isolated from reduction mammoplasty tissue are proliferative for several passage

37 helial cells (HMECs) isolated from reduction mammoplasty tissue of seven individual donors.

38 (HMEC) culture model, derived from reduction mammoplasty tissue, and found that ectopic expression of

39 ionally normal breast tissues from reduction mammoplasty tissues, in what we term the human-in-mouse

40 Adult human skin from reduction mammoplasties was prepared for culture on NetWells or mo

41 e from healthy patients undergoing reduction mammoplasty was also studied.

42 from 40 women undergoing elective reduction mammoplasty were extracted by a solid-phase procedure.

43 (95% CI) for the association of augmentation mammoplasty with SSc were estimated by multivariate logi